StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$87.71M. At the latest close the market valued the company at $462.26M.

Revenue
$0
-100.0% vs. a year earlier
Operating income
-$121.35M
TTM Q2 2026
Free cash flow
-$87.71M
TTM Q2 2026
EPS, diluted
-$5.03
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$462.26M
P/E ratio
–
Price to sales
–
Price to book
2.13
Dividend yield
–
Free cash flow yield
-18.97%

Fundamentals

Revenue
$0
Net income
-$111.11M
EPS, diluted
-$5.03
Free cash flow
-$87.71M
Book value per share
$9.63
Diluted shares
23M

Trading

Next earnings
Mar 23, 2027 (estimated, before the open)
Previous close
$23.30
Open
$23.38
Day's range
$22.21 – $23.38
Volume
278,145
Average volume (20 days)
297,722
Index membership
Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
52-week range
$15.93 – $43.66
RSI (14 days)
39.1
Volatility (1 year)
75.8%
Relative volume
0.89×

On 1 of our idea list: Most shorted (a warning list)

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2014, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodNGNES&P 500DifferenceNGNE per yearS&P 500 per year
1 month-0.6%-4.0%+3.4 pts
3 months-37.0%-5.0%−32.1 pts
Year to date+12.1%+8.2%+3.9 pts
1 year+2.8%+11.2%−8.4 pts
3 years+72.4%+68.5%+3.9 pts+19.9%+19.0%
5 years-80.5%+67.3%−147.7 pts-27.9%+10.8%
10 years-92.1%+291.6%−383.8 pts-22.4%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$121.35M

Net income

-$111.11M

EPS, diluted

-$5.03

Free cash flow

-$87.71M
Reported periodTrailing twelve months

Press releases

Releases Neurogene filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Neurogene

Pharmaceutical Preparations

Neurogene Inc. is a clinical-stage biotechnology company that creates genetic therapies for individuals with severe and rare neurological disorders. The company's primary focus is developing treatments using its proprietary transgene regulation platform, which controls therapeutic protein expression in targeted cells. Its leading clinical asset, NGN-401, is an adeno-associated virus gene therapy designed to treat female pediatric and adult patients suffering from Rett syndrome. The firm operates in the biopharmaceutical sector without commercialized products, directing its investigative programs toward patients and healthcare systems that manage life-threatening central nervous system illnesses.

Company profile, executives and history

Neurogene stock: common questions

What is Neurogene's stock price?

NGNE closed at $23.10 on Nov 17, 2026, down 0.86% on the day. Over the past 52 weeks it traded between $15.93 and $43.66.

What is Neurogene's market cap?

Neurogene was worth $462.26M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is NGNE's P/E ratio?

Neurogene lost money over the twelve months to Jun 30, 2026 (diluted EPS -$5.03), so it has no meaningful P/E ratio.

How much revenue does Neurogene make?

Neurogene reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.

Does Neurogene pay a dividend?

No. Neurogene has not paid a cash dividend over the last twelve months.

When does Neurogene report earnings next?

Neurogene is expected to report Q4 FY2026 results on Mar 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has NGNE stock performed over the past year?

Including dividends, NGNE returned +2.8% over the past year, against +11.2% for the S&P 500.

How many NGNE shares are sold short?

6M shares were sold short at the latest FINRA report, 33.80% of the float, or 16.9 days of average trading volume.

Who are Neurogene's competitors?

Companies most similar to Neurogene by business, industry and size include KRRO, SPRB, OVID, LGVN, RNAC.

See a number that looks wrong?